PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1454251
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1454251
Global external ventricular drain market was valued US$ 6.89 Bn in 2023 and is expected to reach US$ 10.63 Bn by 2031 exhibiting a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2023/2024: | US$ 6.89 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 - 2031 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 5.60% | 2030/2031 Value Projection: | US$ 10.63 Bn |
An external ventricular drain (EVD) is a soft catheter that is inserted via a burr hole into the anterior horn of the lateral ventricle and connected to a closed sterile system to allow for temporary drainage of cerebrospinal fluid (CSF) and/or monitoring of intracranial pressure. Indications for external ventricular drainage are: to relieve raised intracranial pressure, to divert infected CSF, to divert bloodstained CSF following neurosurgery/haemorrhage, to divert the flow of CSF, and to monitor intracranial pressure. External drainage and monitoring is the standard of care for temporarily controlling intracranial pressure by draining cerebrospinal fluid externally from the body. External drainage and monitoring is the temporary drainage of cerebrospinal fluid (CSF) from the lateral ventricles of the brain, or the lumbar space of the spine, into an external collection bag. An external ventricular drainage (EVD) system drains CSF by using a combination of gravity and intercerebral pressure. The drainage rate depends on the height at which the EVD system is placed relative to the patient's anatomy.
Increasing research and development (R&D) activities is expected to drive the growth of the global external ventricular drain market over the forecast period. For instance, in June 2023, Karolinska University Hospital, a hospital based in Sweden, initiated a clinical trial titled "Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections". This study will evaluate three novel diagnostic methods for rapid direct bacterial detection in CSF, in order to assess, if these can be used to guide antibiotic treatment in neurocritically ill patients, as compared to CSF bacterial cultures. The study is expected to get completed by December 31, 2025.